Short-Term Instantaneous Prophylaxis and Efficient Treatment Against SARS-CoV-2 in hACE2 Mice Conferred by an Intranasal Nanobody (Nb22)

Xilin Wu,† Yaxing Wang,† Lin Cheng,† Fengfeng Ni,†,‡, Linjing Zhu,†,‡, Sen Ma,†,‡, Bilian Huang,†, Mengmeng Ji,†, Huimin Hu,†,‡, Yuncheng Li,†,‡, Shijie Xu,§, Haixia Shi,§, Doudou Zhang,§, Linshuo Liu,§, Waqas Nawaz,†, Qinxue Hu,†,‡, Sheng Ye,†,‡,†, Qinxue Hu,†,‡, Sheng Ye,†,‡,†, Yalan Liu,§ and Zhiwei Wu,†,‡,†,11,12*

†Center for Public Health Research, Medical School, Nanjing University, Nanjing, China, 2Department of Antibody, Abrev Biotechnology Co., Ltd., Nanjing, China, 3Tianjin Key Laboratory of Function and Application of Biological Macromolecular Structures, School of Life Sciences, Tianjin University, Tianjin, China, 4Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital, Shenzhen, China, 5State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China, 6Savaid Medical School, University of Chinese Academy of Sciences, Beijing, China, 7School of Life Sciences, Ningxia University, Yinchuan, China, 8Department of Antibody, Y-clone Medical Science Co. Ltd., Suzhou, China, 9Institute for Infection and Immunity, St. George’s University of London, London, United Kingdom, 10Life Sciences Institute, Zhejiang University, Zhejiang, China, 11Jiangsu Key Laboratory of Molecular Medicine, Medical School, Nanjing University, Nanjing, China, 12State Key Laboratory of Analytical Chemistry for Life Science, Nanjing University, Nanjing, China

Current COVID-19 vaccines need to take at least one month to complete inoculation and then become effective. Around 51% of the global population is still not fully vaccinated. Instantaneous protection is an unmet need among those who are not fully vaccinated. In addition, breakthrough infections caused by SARS-CoV-2 are widely reported. All these highlight the unmet need for short-term instantaneous prophylaxis (STIP) in the communities where SARS-CoV-2 is circulating. Previously, we reported nanobodies isolated from an alpaca immunized with the spike protein, exhibiting ultrahigh potency against SARS-CoV-2 and its variants. Herein, we found that Nb22, among our previously reported nanobodies, exhibited ultrapotent neutralization against Delta variant with an IC50 value of 0.41 ng/ml (5.13 pM). Furthermore, the crystal structural analysis revealed that the binding of Nb22 to WH01 and Delta RBDs both effectively blocked the binding of RBD to hACE2. Additionally, intranasal Nb22 exhibited protection against SARS-CoV-2 Delta variant in the post-exposure prophylaxis (PEP) and pre-exposure prophylaxis (PrEP). Of note, intranasal Nb22 also demonstrated high efficacy against SARS-CoV-2 Delta variant in STIP for seven days administered by single dose and exhibited long-lasting retention in the respiratory system for at least one month administered by four doses, providing a
strategy of instantaneous short-term prophylaxis against SARS-CoV-2. Thus, ultrahigh potency, long-lasting retention in the respiratory system and stability at room-temperature make the intranasal or inhaled Nb22 to be a potential therapeutic or STIP agent against SARS-CoV-2.

**Keywords:** SARS-CoV-2, Delta variant, nanobody, Nb22, STIP, structure, instantaneous prophylaxis, instantaneous protection

**BRIEF SUMMARY**

Nb22 exhibits ultrahigh potency against Delta variant *in vitro* and is exploited by crystal structural analysis; furthermore, animal study demonstrates high effectiveness in the treatment and short-term instantaneous prophylaxis in hACE2 mice *via* intranasal administration.

**HIGHLIGHTS**

1. Nb22 exhibits ultrapotent neutralization against Delta variant with an IC₅₀ value of 0.41 ng/ml (5.13 pM).
2. Structural analysis elucidates the ultrapotent neutralization of Nb22 against Delta variant.
3. Nb22 demonstrates complete protection in the treatment of Delta variant infection in hACE2 transgenic mice.
4. We complete the proof of concept of STIP against SARS-CoV-2 using intranasal Nb22 with ultrahigh potency and long-lasting retention in respiratory system.

**INTRODUCTION**

SARS-CoV-2 has given rise to the COVID-19 pandemic (1), resulting in massive disruption of social and economic activities. Global vaccination has provided protection against the
catastrophic outcome of the pandemic. However, a number of individuals are either not fully vaccinated or cannot mount adequate responses to the vaccine. Additionally, current COVID-19 vaccines require multiple doses to achieve full effectiveness and the immunity wanes within a matter of months, which increases the risk of infection and demands the use of agents for providing instantaneous protection at vulnerable times. Several antibodies were approved for emergency use within 7 days of high-risk exposure in the Post-exposure prophylaxis (PEP) against SARS-CoV-2 infection (2, 3). However, there is no licensed agent in preventing infection before exposure to SARS-CoV-2 (i.e., as pre-exposure prophylaxis, PrEP). A few PrEP studies in an animal model demonstrated that antibodies exhibited accelerated clearance of SARS-CoV-2 when administered 1–3 days prior to infection (2, 4–6). The efficacy was not fully explored when antibodies were administered more than three days prior to SARS-CoV-2 infection. To the best of our knowledge, there is no effective intervention to prevent SARS-CoV-2 infection in advance of one week or longer. Therefore, there is a research gap on short-term instantaneous prophylaxis (STIP) that prevention can take effective immediately following antibody infusion and last for one week or longer. As such, STIP is an unmet need for the prevention against SARS-CoV-2.

The Delta variant, also known as B.1.617.2, was first identified in India in December 2020 and has become predominant in many countries, characterized by the spike protein mutations T19R, L452R, T478K, D614G, P681R, D950N and a double deletion at 157–158 (7–10). It has been designated as a Variant of Concern (VOC) and is believed to be 60% more transmissible than the Alpha variant (12). The Delta variant poses a challenge to the available COVID-19 vaccines, such as the protective effectiveness of AstraZeneca and Pfizer vaccines against the Delta variant was reduced to 60 and 88%, respectively (11, 12). More recently, a newly emerged variant, Omicron, has spread rapidly in parts of the world and has drawn attention for its significant resistance to the immune system (13) and has drawn attention for its significant resistance to the immune system (13). The Delta variant poses a challenge to the availability of COVID-19 vaccines, such as the protective effectiveness of AstraZeneca and Pfizer vaccines against the Delta variant was reduced to 60 and 88%, respectively (11, 12). More recently, a newly emerged variant, Omicron, has spread rapidly in parts of the world and has drawn attention for its significant resistance to the immune system (13).

The Delta variant was first identified in India in December 2020 and has become predominant in many countries, characterized by the spike protein mutations T19R, L452R, T478K, D614G, P681R, D950N and a double deletion at 157–158 (7–11). It has been designated as a Variant of Concern (VOC) and is believed to be 60% more transmissible than the Alpha variant (12). The Delta variant poses a challenge to the available COVID-19 vaccines, such as the protective effectiveness of AstraZeneca and Pfizer vaccines against the Delta variant was reduced to 60 and 88%, respectively (11, 12). More recently, a newly emerged variant, Omicron, has spread rapidly in parts of the world and has drawn attention for its significant resistance to the immune system (13–19).

The Delta variant was first identified in India in December 2020 and has become predominant in many countries, characterized by the spike protein mutations T19R, L452R, T478K, D614G, P681R, D950N and a double deletion at 157–158 (7–11). It has been designated as a Variant of Concern (VOC) and is believed to be 60% more transmissible than the Alpha variant (12). The Delta variant poses a challenge to the available COVID-19 vaccines, such as the protective effectiveness of AstraZeneca and Pfizer vaccines against the Delta variant was reduced to 60 and 88%, respectively (11, 12). More recently, a newly emerged variant, Omicron, has spread rapidly in parts of the world and has drawn attention for its significant resistance to the immune system (13–19).

The Delta variant was first identified in India in December 2020 and has become predominant in many countries, characterized by the spike protein mutations T19R, L452R, T478K, D614G, P681R, D950N and a double deletion at 157–158 (7–11). It has been designated as a Variant of Concern (VOC) and is believed to be 60% more transmissible than the Alpha variant (12). The Delta variant poses a challenge to the available COVID-19 vaccines, such as the protective effectiveness of AstraZeneca and Pfizer vaccines against the Delta variant was reduced to 60 and 88%, respectively (11, 12). More recently, a newly emerged variant, Omicron, has spread rapidly in parts of the world and has drawn attention for its significant resistance to the immune system (13–19).

The Delta variant was first identified in India in December 2020 and has become predominant in many countries, characterized by the spike protein mutations T19R, L452R, T478K, D614G, P681R, D950N and a double deletion at 157–158 (7–11). It has been designated as a Variant of Concern (VOC) and is believed to be 60% more transmissible than the Alpha variant (12). The Delta variant poses a challenge to the available COVID-19 vaccines, such as the protective effectiveness of AstraZeneca and Pfizer vaccines against the Delta variant was reduced to 60 and 88%, respectively (11, 12). More recently, a newly emerged variant, Omicron, has spread rapidly in parts of the world and has drawn attention for its significant resistance to the immune system (13–19).
200 (Tecan, Ramsey, MN, USA). Antibody quantification in the sera was calculated according to the standard curve generated by purified antibody.

**Neutralization Activity of Nanobodies Against Pseudovirus**

A pseudovirus neutralization assay was carried out following our previously published protocol (25), with the follow modifications. Briefly, pseudovirus of SARS-CoV-2 variants was produced by cotransfection of pNL4-3.Luc.R-E, an HIV-1 NL4-3 luciferase reporter vector that comprises defective Nef, Env and Vpr (HIV AIDS Reagent Program), and pVAX1 (Invitrogen) expression vectors encoding the spike proteins of respective variants into 293T cells (ATCC). Supernatants containing pseudovirus were collected after 48 h, and viral titers were determined by luciferase assay in relative light units (Bright-Glo Luciferase Assay Vector System, Promega Biosciences). Human codon optimized S genes of SARS-CoV-2 variants were synthesized and constructed as expression plasmids by GenScript. The plasmids were transfected into 293T cells served as a negative control. Neutralization assays were conducted by incubating pseudovirus with serial dilutions of purified nanobodies at 37°C for 1 h. HEK293T-ACE2 cells (cat.# 41107ES03, Yeasen Biotech Co., Ltd, China) (approximately 2.5 x 10^6 per well) were added in duplicate to the virus-antibody mixture. Half-maximal inhibitory concentrations (IC50) of the evaluated nanobodies were determined by luciferase activity 48 h following exposure to virus-antibody mixture, and analyzed by GraphPad Prism 8.01 (GraphPad Software Inc.).

**Expression and Purification of WH01 and Delta RBD Protein for Crystal Structural Analysis**

The WH01 and Delta RBD were expressed using the Bac-to-Bac baculovirus system. The two pAcgp67-RBD (residues 333–530) plasmid with a C-terminal 8×His tag were transfected into Sf9 cells using Cellfectin II Reagent (Invitrogen) to produce the recombinant baculoviruses. After 3 rounds of amplification, Hi5 cells were infected with baculoviruses at an MOI of 4 at a density of 2 x 10^6 cells/ml. The supernatants of cell culture containing the secreted RBD were harvested at 60 h after infection. The RBD was purified by Ni-NTA resin (GE Healthcare). Nonspecific contaminants were removed by washing the resin with 20 mM Tris–HCl, 150 mM NaCl, pH 7.5, and the target proteins were eluted with elution buffer containing 20 mM Tris–HCl, 150 mM NaCl, 500 mM imidazole, pH 7.5. The eluted proteins were further purified by Superdex 75 (GE Healthcare, USA) and stored in 20 mM Tris–HCl, 150 mM NaCl, pH 7.5.

**Expression and Purification of Nb22 for Crystal Structural Analysis**

The VHH gene for Nb22 was amplified by PCR and cloned into a pET21a vector with BamH I and Xho I restriction sites. The recombinant plasmids were transformed into *Escherichia coli* BL21 (DE3). The cells were cultured in LB medium and grown to OD_600 = 0.8 at 37°C. Isopropyl-D-1-thiogalactopyranoside (IPTG) was added to a final concentration of 1.0 mM to induce the protein expression, and the cultures were grown at 16°C overnight. Cells were harvested by centrifugation at 4,500 rpm for 15 min, re-suspended and homogenized in the lysis buffer containing 20 mM Tris–HCl, 150 mM NaCl, pH 7.5 using ultrasonic. Cell debris was removed by centrifugation at 18,000 rpm for 30 min. The supernatants were added to Ni-NTA resin (GE Healthcare, USA). The nonspecific contaminants were eluted by washing the resin with the lysis buffer containing 10 mM imidazole. The target protein with 6×His tag, named as Nb22, was subsequently eluted with the lysis buffer containing 500 mM imidazole. Nb22 was eluted and purified by Superdex 75 (GE Healthcare, USA).

**Crystallization, Structural Determination and Data Acquisition**

The complexes were prepared by mixing WH01 or Delta RBD and Nb22 at a 1:1.2 molar ratio and incubating at 4°C overnight. The complexes were further purified by Superdex 75 (GE Healthcare, USA).
Healthcare, USA) to remove the excess nanobody. The crystals were screened by vapor-diffusion sitting-drop method at 16°C. The crystals appeared and reached their final size within 3 days in a well solution comprising 0.1 M HEPES (pH 7.0), 5% v/v (+/−)-2-Methyl-2,4-pentanediol (MPD), 10% polyethylene glycol (PEG) 10,000 (WH01 RBD-Nb22) and 0.1 M Tris (pH 7.0), 37.5% Jeffamine (Delta RBD-Nb22), respectively.

To collect data, a single crystal was mounted on a nylon loop and was flash-cooled with a nitrogen gas stream at 100 K. Diffraction data of WH01 RBD-Nb22 was collected on BL18U1 at the Shanghai Synchrotron Radiation Facility (SSRF) at a wavelength of 0.97915 Å. While, the Delta RBD-Nb22 was collected on BL02U1 at a wavelength of 0.97918 Å. Data were processed and scaled using the HKL3000 package and autoPROC (29). The structures were elucidated using the molecular replacement (MR) method in PHASER program (30) with the structure of SARS-CoV-2 RBD (PDB code: 7CJF) (31) as the initial searching model. The model was built into the modified experimental electron density using COOT (32) and further refined in PHENIX (33). The final refinement statistics are summarized in Table S1. Structural figures were prepared by PyMOL. Epitope and paratope residues, and their interactions, were identified by PISA (http://www.ebi.ac.uk/pdbe/prot_int/pistart.html) at the European Bioinformatics Institute.

**Pharmacokinetics (PK) of Nb22-Fc In Vivo**

Purified Nb22-Fc were injected via intranasal (i.n.) into BALB/c mice (Qing Long Shan Animal Center, Nanjing, China) at a dose of 10 mg/kg. The concentration of Nb22-Fc in serum was measured by ELISA. The T1/2 of Nb22-Fc was calculated as ln (2)/k, where k is a rate constant expressed reciprocally of the x axis time units by the plateau followed one phase decay or one phase decay equation in the GraphPad software.

**Spatial Distribution of Nb22-Fc In Vivo**

Spatial distribution of Nb22-Fc were conducted following our previously published protocol (25), with minor modifications. Nb22-Fc labeled with far infrared dye YF750 SE (US EVERBRIGHT INC., YS0056) were named as Nb22-YF750. Approximately10 mg/kg Nbs-YF750 was administered via intranasal into nude mice (18-22 g, Qing Long Shan Animal Center, Nanjing, China). Images were recorded at Ex.740 nm/Em.780 nm by NighOWL LB 983 (Berthold, Germany) at the indicated time point. Images were analyzed using Indigo imaging software Ver. A 01.19.01.

**Evaluating the Efficacy of Nb22-Fc in SARS-CoV-2 Infected hACE2 Mice**

The efficacy of Nb22-Fc against SARS-CoV-2 were evaluated according to our previously published protocol (25), with minor modifications. In brief, a total of 43 8-week-old male transgenic hACE2 mice (C57BL/6j) (cat.# T037630, GemPharmatech Co., Ltd., Nanjing, China) were challenged with 1 x 10⁶ PFU SARS-CoV-2 Delta variant (CRST: 1633.06.IVCAS 6.7593) per mouse. The mice were randomly divided into nine groups (n = 3–6) for either prophylactic or therapeutic evaluation, as described in Figure 5A. Mice without any treatment and challenge were taken as blank control (No SARS-CoV-2, n = 3). Mice challenged with SARS-CoV-2 were taken as infection control (SARS-CoV-2, n = 5). Approximately250 µg/mouse (average of 10 mg/kg) SNB02 (Y-Clone, China), an anti-SFTSV antibody constructed by Nb fused with human Fc (Nb-Fc) (26), was intranasally injected 1 h after infection and was taken as an isotype antibody treated control (Control Nb, n = 3). For the prophylactic group, mice were intranasally injected with Nb22-Fc at a dose of 250 µg/mouse (average of 10 mg/kg) at 7 days (d), 5, 3, and 1 d before infection (named as −7d Nb22, −5d Nb22, −3d Nb22, and −1d Nb22, respectively, n = 5–6). For the therapeutic group, mice were intranasally injected with Nb22-Fc at a dose of 250 µg/mouse (average of 10 mg/kg) 1 h or 24 h after infection (named as 1h Nb22 and 1d Nb22, n = 5, respectively). The body weight of the mouse was recorded daily. Given that hACE2 transgenic mice typically clear virus within 5–7 days after SARS-CoV-2 infection (34), the mice were sacrificed at 4 days post infection (dpi). Subsequently, lung tissues were harvested for viral load determination and tissue sections for immunofluorescence (IF) and hematoxylin and eosin (H&E) staining. All experiments were conducted in a Biosafety Level 3 (BSL-3) facility.

**Viral Load Measurement by Quantitative RT-PCR**

Viral load was measured by quantitative real-time PCR (qRT-PCR) on RNA extracted from the supernatant of lung homogenates as reported previously (35). Briefly, lung homogenates were prepared by homogenizing perfused lung using an electric homogenizer. The inactivated samples were transferred from the BSL-3 to BSL-2 laboratory and total RNA was extracted from the collected supernatant. Each RNA sample was reverse transcribed to 50 µl cDNA with HiScript II Q RT SuperMix for qPCR (+gDNA wiper) (RR23-01). Approximately 5 µl cDNA was added into a 25 µl qRT-PCR reaction containing the ChamQ SYBR qPCR Master Mix (High ROX Premixed) (Q341-02, Vazyme Biotech, China) and primers designed to target the nucleocapsid protein of SARS-CoV-2 (5′-GGGAACATTCTCCTCTGATAAT-3′ and 5′-CAGACATTTCGCTCAAGCTG-3′). The samples were run in triplicate on an ABI 7900 Real-Time System (Applied Biosystems, Thermo Fisher Scientific). The following cycling conditions were performed: 1 cycle of 50°C for 2 min, 1 cycle of 95°C for 10 min, and 40 cycles of 95°C for 15 s and 58°C for 1 min.

**Immunofluorescence Staining of SARS-CoV-2-Infected Cells and H&E Staining in Tissues**

The lung tissues were immersed in 10% neutral buffered formalin (cat.# Z2902, Sigma) for 24 h. After the formalin fixation, the tissues were placed in 70% ethanol (Merck) and subsequently embedded with paraffin. Tissue sections (5-µm thick) were prepared for H&E staining and immunofluorescence staining for SARS-CoV-2 detection using the Coronavirus nucleocapsid protein (NP) antibody (cat. 40143-MM05, Sino Biological). Sections stained by H&E were scored for pathological severity of disease on a scale of 0 to 5 grades according to the
inflammatory factors invasion and the alveoli integrity (36). Images were collected under a Pannoramic MIDI system (3DHISTECH, Thermo) using Pannoramic scanner software and analyzed by ImageJ (NIH).

Statistics
All statistical analyses were carried out using GraphPad Prism 8.01 software (GraphPad) or OriginPro 8.5 software (OriginLab). ANOVA or Mann–Whitney test was performed for group comparisons. $P < 0.05$ was considered as statistically significant with mean ± SEM or mean ± SD.

RESULTS

Potent Neutralization of Delta Variant by Nanobodies
We previously reported the discovery and characterization of three potent neutralizing nanobodies against the WH01 strain and its variants with $IC_{50}$ values of ~1 ng/ml. These three nanobodies (Nb15-Fc, Nb22-Fc, and Nb31-Fc) were identified to bind to RBD (25). Neutralization experiments were further conducted to measure their activity against the circulating variants including variants of concern (VOC) comprising Alpha (B.1.1.7 with N501Y), Beta (B.1.351 with E484K and N501Y), Delta (B.1.617.2 with L452R and T478K) and Gamma (P.1 with K417T, E484K and N501Y), and also variants of interest (VOI) comprising Eta (B.1.525 with E484K), Iota (B.1.526 with E484K), Epsilon (B.1.429 with L452R), and Kappa (B.1.617.1 with L452R and E484Q) (7–10). Nb15-Fc exhibited increased potency against the Alpha variant, but decreased potency against the Delta variant or Epsilon as compared with the WH01, the RBD used to select the nanobodies. Nb31-Fc exhibited reduced potency against the Alpha, Delta and Epsilon variants relative to the WH01 or D614G variant (Figure 1A–G). Interestingly, Nb22-Fc exhibited about 2.5-fold increased neutralizing potency against the Delta variant with an $IC_{50}$ value of 0.41 ng/ml (5.13 pM) compared to the WH01 with an $IC_{50}$ of 1.01 ng/ml (12.63 pM). Notably, Nb22-Fc also exhibited around 4-fold increased neutralization potency against the Delta variant relative to variant Alpha with an $IC_{50}$ of 3.45 ng/ml (43.13 pM) (Figures 1A–G). Impressively, Nb22-Fc also exhibited outstanding neutralizing curve against the authentic Delta variant compared to Nb15-Fc and Nb31-Fc (Figures 1A–G). All three nanobodies failed to neutralize the variants containing the E484K/Q mutation, suggesting that the E484K/Q mutation in RBD could lead to the resistance to all three nanobodies.

Altogether, Nb15-Fc presented the most potent neutralization against the variant Alpha with an $IC_{50}$ of 0.18 ng/ml, and Nb15-Fc and Nb31-Fc still retained potent neutralization of variants containing L452R and T478K mutations in RBD (Figures 1E, G), though with reduced potency like most other anti-RBD antibodies (7, 12). Of note, Nb22-Fc exhibited the most potent neutralization against pseudotyped or the authentic Delta variant virus among three nanobodies (Figures 1A–G).

Characterization of Nb22-Fc Binding to RBD
To explore antibody binding characteristics to the RBD with respect to their neutralization of the Delta variant, the interactions of three nanobodies with variant RBDs were analyzed using biolayer interferometry (BLI). Nb15-Fc, Nb22-Fc and Nb31-Fc showed high affinity interactions with the RBD of the Delta variant at 1.86, 0.31, and 0.31 nM, respectively (Figures 2A–C). However, the ultrahigh affinity of Nb22-Fc and Nb31-Fc to the RBD of the Delta variant did not fully reflect the neutralization potency as Nb22-Fc neutralized the Delta variant with markedly more potency than that of Nb31-Fc, suggesting that affinity is not the only factor dictating the neutralization activity. Furthermore, Nb22-Fc exhibited increased affinity with the Delta variant RBD relative to other variant RBDs (Figure 2D), which is in line with the increased potency conferred by Nb22-Fc against the Delta variant as compared with other variants.

Moreover, immunofluorescence analysis revealed that Nb22-Fc specifically interacted with spike protein from the WH01, D614G, Alpha, Epsilon and Delta variants on the surface of transfected 293T cells, whereas no binding with the spike protein from other variants containing E484K/Q mutation (Figure 2E). These results were substantiated by flow cytometric results (Figure 2F). Overall, these specific binding characteristics are consistent with its specific neutralization properties.

Structural Analysis of RBD-Nb22 Complex
Structural analysis of Nb22 interaction with RBD was performed to address the ultrahigh potency of Nb22 against the WH01 strain and the Delta variant. Initially, we determined the crystal structure of the WH01 RBD-Nb22 complex at a resolution of 2.7 Å (Figure 3A and Table S1). Nb22 adopts a typical ß-barreled structure, and contains three variable complementarity-determining regions (CDR) binding to RBD. The buried surface area (BSA) was 800 Å$^2$, mainly constituting of hydrogen bonds and hydrophobic interactions. A total of 14 residues constituting epitope of three CDRs were identified using a distance of <4 Å as the cutoff (Figure 3B). For CDR1, T30, and S33 formed two hydrogen bonds with S494 of RBD, while the hydrophobic interactions included A32 and F34 of Nb22 and Y449, L452, F490 and Q493 of RBD (Figure 3C and Table S2). N57 of CDR2 interacted with G485 by hydrogen bond, and the hydrophobic interactions were mediated by I56 and Y489 (Figure 3D). CDR3 is a relatively longer region with only one hydrogen bond (Y119 and G446). The side chain of P104 inserted into the hydrophobic cavity formed by F101, R107, Y453, F456, and Y495 (Figure 3E). Apart from the five hydrogen bonds in CDR regions, the interface of Nb22 and RBD was stabilized by two additional hydrogen bonds consisting of G1, S75, N450, and E484 (Figure 3F). Interactions were also facilitated by the hydrophobic network constituted by P2, Q3, V4, G28, G29, R73, and D74 of Nb22 (Figure 3G and Table S2).

Superimposition of the structure of the WH01 RBD-Nb22 complex and RBD-hACE2 (PDB code: 6MOJ) immediately elucidates the structural basis of neutralization, in which the
binding of Nb22 to RBD effectively blocks the binding of RBD to hACE2 during virus infection. Firstly, the binding site of Nb22 on RBD partially overlaps with that of hACE2 (Figure S1A). Secondly, the loop (V102-Y117) of Nb22 clashes with two α-helices of the N-terminus of hACE2 (Figure S1B).

To elucidate the increased potency of Nb22 in neutralizing the Delta variant, we determined the Delta RBD-Nb22 complex structure at a resolution of 2.9 Å, which revealed that two distinct mutations, T478K and L452R, had differing impact on the binding. K478 locates outside the CDR binding regions, and does not disturb the interaction surface (Figure 4A and Table S1). Therefore, T478K mutation does not affect Nb22 neutralization (Figure 4A). However, the mutation of hydrophilic leucine to positively charged arginine (R) at position 452 significantly enhances the interactions of RBD with the CDR3 region of Nb22. Two additionally formed hydrogen bonds, T30-R452 and S33-Q493, pull the CDR3 loop of Nb22 closer to R452 region of RBD, as revealed by the superimposition of the structures of WH01 and Delta RBD-Nb22 (Figures 4B, C and Table S2), explaining enhanced neutralization activity of Nb22 against the Delta variant.

**Figure 1** Characterizing nanobodies neutralizing circulating variants of SARS-CoV-2. The neutralization curve of Nb15-Fc (A), Nb22-Fc (B), Nb31-Fc (C), and SNB02 (D) inhibiting SARS-CoV-2 pseudovirus of circulating variants. Nb-Fcs and SNB02 were all constructed as the format of VHH fused with human Fc1. SNB02 was taken as an antibody control specific for SFTS virus. The summary curve of IC50 of Nb-Fcs exhibiting potent neutralization against SARS-CoV-2 variants. The neutralization potency of Nb-Fcs was evaluated based on authentic SARS-CoV-2 Delta variant plaque reduction neutralization test. The summary table of IC50 and IC80 of Nb-Fcs in panels (A–C, F), displaying potent neutralization. Data are represented as mean ± SD. All experiments were repeated at least twice.

**Nb22 Exhibits Room-Temperature Stability In Vitro and Long-Lasting Retention In Vivo**

Nanobodies exhibit various advantages including thermostability. We reported that nanobodies could retain 100% activity even after being incubated at 70°C for 1 h and retain 83% activity after 80°C
treatment for 1 h (25). Further evaluation showed that Nb22 could maintain full activity for at least two months at room temperature and did not lose any activity even undergoing five rounds of freeze-thawing (Figures 5A, B), indicating that Nb22-Fc is highly stable and idea for non-cold chain storage and use at room-temperature.

To determine Nb22-Fc distribution in vivo, YF750 SE-labeled Nb22 (Nb22-YF750) was administered via intranasal (i.n.) in a mouse model. The fluorescence could be readily detected in the respiratory system including nasopharynx, trachea, and lung 2 h post infusion. The fluorescence was detectable for more than seven days after a single dose of 200 µg (average of 10 mg/kg) Nb22-YF750 administration, which is in agreement with our previous reports.

As expected, the fluorescence could be detected for more than one month when four doses of 200 µg (average of 10 mg/kg) Nb22-YF750 were administered every week (Figures 5C–E and Figure S2). Nb22-Fc could also be detected in the blood, indicating that Nb22-Fc could also exert its activity in the blood after bypassing the respiratory system (Figure 5F). All these observations of prolonged retention of Nb22-Fc in the respiratory system suggest the potential application of the antibody for STIP against SARS-CoV-2 infection. Taken together, intranasal Nb22-Fc could be developed as a STIP reagent for its long-lasting retention in the respiratory system and a portable therapeutics thanks to its room-temperature stability.
Intranasal Nb22 is Highly Efficacious in the STIP, PreP and PeP in hACE2 Transgenic Mice Challenged by the Delta Variant

To evaluate the efficacy of Nb22-Fc \textit{in vivo}, hACE2 transgenic mice were challenged with $1 \times 10^5$ PFU SARS-CoV-2 Delta variant (CRST: 1633.06.IVCAS 6.7593) and conducted as we previously reported (25). hACE2 mice were divided into nine groups ($n = 3$–6) as shown in Figure 6A and 200 μg (average of 10 mg/kg) Nb22-Fc was administered via i.n. before or after Delta variant challenge to evaluate the prophylactic or therapeutic efficacy of the antibody against Delta variant infection. Viral RNA in the lungs was detected in virus control group named as SARS-CoV-2 group (Group 2). Animals in Control Nb group Group 3 were challenged with the Delta variant and received control nanobody treatment 1 h post infection. As expected, high copy numbers of viral RNA were also detected in control Nb mice without significant difference compared to SARS-CoV-2 group (Figure 6B).

In order to evaluate the prophylactic duration conferred by Nb22, a single dose of Nb22 was administered via i.n. at days 1, 3, 5, and 7, respectively, prior to Delta variant challenge. Viral RNA copies increased over the course of Nb22-Fc administration (Figure 6B). As expected, viral RNA copies in the aforementioned prophylactic groups were all significantly lower than that in the control Nb group, indicating that even a single dose of Nb22-Fc could provide protection against Delta variant infection in hACE2 transgenic mice for 7 days. Nb22 administered in −7d and −5d before challenge significantly
reduced viral load though failed to provide complete protection (Figure 6B). Notably, Nb22 exhibited significant prevention against SARS-CoV-2 infection in the −3d Nb22 (Group 6) and −1d Nb22 group (Group 7) (Figure 6B). All these indicate that Nb22-Fc provides better protection at the earlier time points upon infection.

In the therapeutic group, viral RNA copies in the animals treated with Nb22 at 1 h or 1 day postinfection were undetectable in 5/5 mice in the groups 8 and 9, suggesting that Nb22 had complete protection of hACE2 mice against Delta variant infection (Figure 6B). The viral RNA results were also validated by immunofluorescence (IF) staining and HE staining in the lungs (Figures 6C, D, 7). Compared with uninfected healthy mice, mice treated with Nb22 showed mild or limited alveolar septal infiltration and peribronchiolar infiltration. In contrast, control SARS-CoV-2 infected mice or mice treated with control Nb showed large patchy areas of alveolar space and alveolar wall involvement by inflammatory infiltrates and exudation (Figures 6D, 7). We noted that mice challenged by the Delta variant did not show obvious weight loss even in 4 days post infection (Figure S3). In summary, Nb22 exhibited high efficacy in both the prevention and therapy of hACE2 transgenic mice challenged with the Delta variant. Nb22 provided complete protection in PEP (in 1h Nb22 group and 1d Nb22 group) and exhibited high efficacy in PrEP (in −1d Nb22 and −3d Nb22 group). Impressively, a single dose of Nb22 could maintain effectiveness in the prevention against Delta variant infection for at least seven days (in −7d Nb22 group), indicating the potential application for STIP against SARS-CoV-2.
DISCUSSION

To date, a small number of nanobodies with ultrahigh potency against SARS-CoV-2 and its variants have been reported (15, 37, 38), whereas nanobodies with potent neutralization against the currently dominant Delta variant were rarely reported. Our results revealed that three previously reported nanobodies (25), retained ultrahigh potency in neutralization against the Delta variant. Among them, Nb22-Fc with an IC_{50} value of 0.41 ng/ml (5.13 pM) is outstanding with increased neutralization of the Delta variant relative to the Alpha variant. The Nb22 binding to RBD provides mechanistic insight into the enhanced neutralization against the Delta variant, suggesting that the increased binding affinity enhanced the neutralizing potency against the Delta variant relative to the Alpha variant (Figure 1). Given that most anti-RBD, anti-NTD antibodies or

![Image](https://example.com/image.png)

**FIGURE 5** | Characterizing Nb22-Fc stability in vitro and pharmaceutics in vivo. (A) Binding curve of RBD with Nb22-Fc detected by ELISA after storage at room temperature in the indicated time points, namely, 0, 5, 10, 30, 40, 50, and 60 d. (B) Binding curve of RBD with Nb22 detected by ELISA after the indicated rounds of freeze-thawing, namely, 0, 1, 3, and 5 rounds, respectively. (C) Pharmacokinetic of Nb22-Fc labeled with dye YF®750 SE via intranasal administration was detected. Approximately 200 μg Nb22-YF750 was infused at days 0, 7, 14, and 21 respectively. The optical imaging of mouse upper half body was measured by NightOwl LB 983 0.08 d (2 h) post Nb22-Fc infusion or at indicated time point labeled at the top of panel. The mice in the red dash line figure were sacrificed at the indicated time point in the left of panel for analysis of the fluorescence intensity of lung. (D) The fluorescence intensity of upper half body of mice in panel (C) was summarized. (E) The fluorescence intensity of lung in lung column of (C) was summarized. (F) Bioavailability and t_{1/2} of Nb22 in BALB/c mice. Nb22 was intranasally (i.n.) administered into mice (n = 3, Female) at 200 μg (average of 10 mg/kg mice. Serum concentrations of the Nbs were determined at various time points by ELISA. T_{1/2}, time of half-life. Data represent mean ± SEM.
convalescent sera or vaccine-elicited antibodies showed reduced neutralization of the Delta variant relative to that of the Alpha variant (7, 12), the increased neutralization activity of Nb22-Fc against the Delta variant is particularly striking and the structural basis of the phenomenon is of interest for understanding the neutralization mechanisms.

The structural analysis further illustrated the characteristics of Nb22 binding to WH01 and Delta RBD and the mechanisms of viral entry and neutralization. The efficacy of Nb22s evaluated in hACE2 transgenic mice challenged by SARS-CoV-2 is shown in Figure 6. The experimental schedule, viral loads in lungs, and histopathological analysis were compared among groups to assess the protective and therapeutic effects of Nb22. The data are represented as mean ± SEM, and statistical analysis was performed using the Mann–Whitney test.

**Figure 6** | The efficacy of Nb22s evaluated in hACE2 transgenic mice challenged by SARS-CoV-2. (A) Experimental schedule of Nb22s in the prevention and treatment of SARS-CoV-2 infection. Bottom, table summary of groups (n = 3–6 mice) with different treatments. (B) Viral loads in lungs among 9 groups were measured by qRT-PCR. The name of each group in the x axis was indicated as in the table in panel (A). Each dot represents one mouse. The limit of detection was 1,000 copies/mg referenced to blank control (No-SARS-CoV-2 group). Data are represented as mean ± SEM; Mann–Whitney test was performed to compare treatment group with the SARS-CoV-2 control group. (C) Sections of lung were analyzed by immunofluorescence staining using antibodies specific to SARS-CoV-2 NP in red and DAPI for nuclei in blue, respectively. The fluorescence signal intensity of red was taken as a quantitative indicator for viral infection, which was calculated by ImageJ software. (D) Sections of lung were analyzed by H&E staining, which were scored for pathological severity of disease on a scale of 0 to 5 grades according to the alveoli integrity and the inflammatory factors invasion. ns, no significance; *p <0.05, **p <0.01, ****P < 0.0001. All experiments of panels (B, C) were repeated twice.
of viral inhibition. Nb22 binding to RBD effectively blocks the binding of RBD to hACE2 during virus infection. The binding site of Nb22 on RBD overlaps with that of hACE2 (Figure S1A), and the loop (V102-Y117) of Nb22 clashes with two α-helices of the N-terminus of hACE2 (Figure S1B). In addition, crystal structural analysis showed that T478K mutation of the Delta variant are located outside 800 Å² BSA of Nb22 interacting with RBD and do not perturb the interaction between Nb22 and the RBD of the Delta variant. Of note, the guanidine moiety in the L452R mutation forms an additional hydrogen bond between the hydroxyl group of T30 of Nb22, pulling the CDR3 loop of L452R mutation forms an additional hydrogen bond with RBD of the Delta variant. Of note, the guanidine moiety in the RBD and do not perturb the interaction between Nb22 and the variant are located outside 800 Å² BSA of Nb22 interacting with the N-terminus of hACE2 (Figure S1B). Consequently, the BSA extends from 800 to 835 Å², in comparison with that of Nb22-WH01 RBD. All these contribute to the enhanced binding and neutralizing potency of Nb22 against the Delta variant.

Figure 7: Representative sections of lung from hACE2 mice were analyzed by H&E staining and immunofluorescence staining. Representative lung tissue sections from the mice indicated in Figure 6C, namely, No-SARS-CoV-2, SARS-CoV-2, Control Nb, −7d-Nb22, −5d-Nb22, −3d-Nb22, 1h-Nb22, and 1d-Nb22 group were analyzed by immunofluorescence staining using antibodies specific to SARS-CoV-2 NP in red and DAPI for nuclei in blue, respectively. The corresponding representative lung tissue sections were also analyzed by H&E staining. Immunofluorescence and HE Images were visualized under the indicated bar.

Compared to conventional antibodies for passive immunization, nanobodies are effectively produced in prokaryotic expression systems at low cost and possess favorable biophysical properties including high thermostability (39). We reported that nanobodies could remain 100% activity even incubated at 70 °C for 1 h and are amenable to engineering of multimeric nanobody constructs (25). Such nanobodies exhibit high effectiveness against virus infection via intranasal administration (25). The results reveal that Nb22 could maintain full activity for more than two months at room temperature and does not lose any activity even after undergoing five rounds of freeze-thawing.

Our results demonstrate that a single dose of intranasal Nb22 could exhibit efficacy in the STIP, PrEP, and PEP against SARS-CoV-2 infection in hACE2 mice. Of note, a single dose of intranasal Nb22 could maintain efficacy against SARS-CoV-2 infection for at least one week in hACE2 mice, which would readily serve as STIP. Our antibody distribution results also revealed that Nb22 could retain in respiratory tracts for at least one month when weekly administered via i.n. As such, we anticipate that Nb22 could provide one month prevention against SARS-CoV-2 infection when administered intranasally every week.

Long-term lagging prevention against SARS-CoV-2 conferred by approved vaccine usually takes more than one month to be effective and then lasts for months or years (40). Vaccine efficacy has been shown to wane within months after vaccination (7, 11). Instantaneous prevention of SARS-CoV-2 is also needed for individuals who do not take vaccines when SARS-CoV-2 is circulating. A few studies in animal model demonstrated that antibodies exhibited accelerated clearance of SARS-CoV-2 in PrEP when administered 1–3 days prior to infection (2, 4–6). Whereas, to the best of our knowledge, few studies have fully investigated the STIP that prevention could be readily effective immediately following inoculation and last for more than one week to one month for people at high risk of SARS-CoV-2 infection, which can also serve to reduce transmission during the asymptomatic stage of the infection. As such, our results demonstrate that intranasal Nb22 with ultrahigh potency and long-lasting retention in the lung could satisfy the need of STIP against SARS-CoV-2.

In summary, structural analysis provides a mechanistic explanation to the enhanced sensitivity of the Delta variant and the increased neutralization potency of this antibody. The structural analysis may further guide the rational design of pan-coronavirus vaccines and therapeutics. Nb22 exhibited one of the ultrahigh neutralization potencies among the reported antibodies or nanobodies against Delta variant infection (7, 12, 37, 41, 42). We presented proof of concept of STIP against SARS-CoV-2 using our Nb22 and suggest STIP as a new prophylactic strategy for long-lasting antibodies to prevent virus infection. Although the newly emerged Omicron variant is spreading globally, the Delta variant is significantly more severe than Omicron; therefore, the ultrahigh potent, and thermal stable Nb22 is an excellent candidate for intranasal or inhalable anti-SARS-CoV-2 agent for both therapy or prophylaxis, especially including STIP.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

ETHICS STATEMENT

The animal study was reviewed and approved by the recommendations for care and use of the Institutional Review
Board of Wuhan Institute of Virology of the Chinese Academy of Sciences (Ethics Number: WIVA11202111).

**AUTHOR CONTRIBUTIONS**

XW conducted most experiments, analyzed the data and wrote the draft manuscript. LC conducted all the neutralization experiments. LZ, BH, MJ, SX, HS, DZ, LL, and WN provided technical assistance. YW, SM, and SY conducted the structural analysis. FN, YCL, HH, QH, and YLL evaluated the efficacy of Nb22 in SARS-CoV-2 infected transgenic hACE2 mice. ZW designed the study, directed and revised the manuscript. All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

**FUNDING**

This work was supported by the National Science Foundation of China (NSFC) (Nos. 81803414 to XW and 31970172 to YL), the Central Universities (Grant #ZDA2020014 to XW), the Fundamental Research Funds for the Central Universities (Grant #2021-ZD008), the Key National Science Foundation of Jiangsu Province (Grant #ZDA2020014 to XW), the China Postdoctoral Science Foundation (Grant #2019M651850 to ZW), the Ministry of Science and Technology (2020YFA0908500 to SY), the Tianjin Natural Science Foundation (20JCNJQ01570 to YW), the Jiangsu Province (Nos. 81803414 to XW and 31971127 to SY and 81801998 to YW), the Tianjin Natural Science Foundation (20JQQNJC01570 to YW), the Nanjing University (Grant #0214-14380523 to XW), the Tianjin Natural Science Foundation (20JQQNJC01570 to YW), the Nanjing University–Ningxia University Collaborative Project (Grant #2017BN04 to ZW), the Jiangsu Province Natural Science Foundation for Young Scholar (Grant #BK20170653 to XW), the Key National Science Foundation of Jiangsu Province (Grant #ZDA2020014 to XW), the Fundamental Research Funds for the Central Universities (Grant #2021-ZD008), the Jiangsu province “Innovative and Entrepreneurial talent” and Six Talent Peaks Project of Jiangsu Province, the Emergency Prevention and Control Capacity Program for New Severe Infectious diseases of National Institute for Viral Disease Control and Prevention, and the 135 Strategic Program of Chinese Academy of Sciences, the Science and Technology Innovation Committee of Shenzhen Municipality (CJYJ20180228162229889 to LC), and the National Science Foundation of China (No. 31970172 to YL).

**ACKNOWLEDGMENTS**

We thank Prof. Guo for providing the plasmid of RBD. The X-ray data were collected using the Shanghai Synchrotron Radiation Facility on BL18U1 and BL02U1. The efficacy of Nb22 in SARS-CoV-2 infected transgenic hACE2 mice was evaluated in the Wuhan National Biosafety Laboratory, Chinese Academy of Sciences.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.865401/full#supplementary-material

**REFERENCES**

1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A Pneumonia Outbreak Associated With a New Coronavirus of Probable Bat Origin. Nature (2020) 579(7798):270–3. doi: 10.1038/s41586-020-2021-7
2. Baum A, Ajithdoss D, Copin R, Zhou A, Lanza K, Negron N, et al. REGN-COV2 Antibodies Prevent and Treat SARS-CoV-2 Infection in Rhesus Macaques and Hamsters. Sci (New York NY) (2020) 370(6520):1110–5. doi: 10.1126/science.abe2402
3. Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients With Covid-19. N Engl J Med (2021) 384(3):229–37. doi: 10.1056/NEJMa2029849
4. Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Nkolola JP, et al. Potently Neutralizing and Protective Human Antibodies Against SARS-CoV-2. Nature (2020) 584(7821):443–+. doi: 10.1038/s41586-020-2548-6
5. Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He WT, et al. Isolation of Potent SARS-CoV-2 Neutralizing Antibodies and Protection From Disease in a Small Animal Model. Science (2020) 369(6506):956–63. doi: 10.1126/science.abc7520
6. Pymm AD, Adair A, Chan LI, Cooney JP, Mordant FL, Allison CC, et al. Nanobody Cocktails Potently Neutralize SARS-CoV-2 D614G NS01Y Variant and Protect Mice. Proc Natl Acad Sci USA (2021) 118(19): e2101918118. doi: 10.1073/pnas.2101918118
7. Liu C, Ginn HM, Dejamhurais W, Supasa P, Wang B, Tyszkaphon A, et al. Reduced Neutralization of SARS-CoV-2 R.1.617 by Vaccine and Convalescent Serum. Cell (2021) 184(16):4220–36.e13. doi: 10.1016/j.cell.2021.06.020
8. Garcia-Beltran WN, Lam EC, St. Denis K, Nittido AD, Garcia ZH, Hauser BM, et al. Multiple SARS-CoV-2 Variants Escape Neutralization by Vaccine-Induced Humoral Immunity. Cell (2021) 184(9):2372–83.e9. doi: 10.1011/2021.02.14.21251704
9. Davies NG, Jarvis CJ, Edmunds WJ, Jewell NP, Diaz-Ordaz K, Keogh RH. Increased Mortality in Community-Tested Cases of SARS-CoV-2 Lineage B.1.1.7. Nature (2021) 593(7858):270–4. doi: 10.1101/2021.02.01.21250959
10. Plante JA, Mitchell BM, Plante KS, Debbink K, Weaver SC, Menachery VD. The Variant Gambit: COVID-19’s Next Move. Cell Host Microbe (2021) 29(4):508–15. doi: 10.1016/j.chom.2021.02.020
11. Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 Vaccines Against the B.1.617.2 (Delta) Variant. N Engl J Med (2021) 385(7):585–94. doi: 10.1056/NEJMoa210527658
12. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guvel-Benhassine F, Rajah MM, et al. Reduced Sensitivity of SARS-CoV-2 Variant Delta to Antibody Neutralization. Nature (2021) 596(7871):276–80. doi: 10.1038/s41586-021-03777-9
13. Hall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. AZD1222-Induced Neutralising Antibody Activity Against SARS-CoV-2 Delta VOC. Lancet (2021) 398(10296):207–9. doi: 10.1016/s0140-6736(21)00462-9
14. Yadav PD, Sapkal GN, Abraham P, Ella R, Deshpande G, Patil DY, et al. Neutralization of Variant Under Investigation B.1.617 With Sera of BBV152 Vaccines. Clin Infect Dis an Off Publ Infect Dis Soc Am (2021) 74(3):366–8. doi: 10.1093/cid/ciaa4101
15. Wang L, Zhou T, Zhang Y, Yang ES, Schramm CA, Shi W, et al. Ultrapotent Antibodies Against Diverse and Highly Transmissible SARS-CoV-2 Variants. Sci (New York NY) (2021) 373(6556):eabh1766. doi: 10.1126/science.abh1766
16. Xiang Y, Nambooli S, Xiao Z, Liu H, Sang Z, Duprex WP, et al. Versatile and Innovative and Entrepreneurial talent and Six Talent Peaks Project of Chinese Academy of Sciences, the Science and Technology Innovation Committee of Shenzhen Municipality (CJYJ20180228162229889 to LC), and the National Science Foundation of China (No. 31970172 to YL).
Wu et al. STIP Against SARS-CoV-2 by Nb22

Inactive Spike. Sci (New York NY) (2020) 370(6523):1473–9. doi: 10.1101/2020.08.08.238469

18. Huo Y, Liu J, Zhao X, Rusa RR, Duveystein YM, Mikolajek H, Malinauskas T, et al. Neutralizing Nanobodies Bind SARS-CoV-2 Spike RBD and Block Interaction With ACE2. Nat Struct Mol Biol (2020) 27(9):846–+. doi: 10.1038/s41594-020-0469-6

19. Hanke L, Perez LV, Sheward DJ, Das H, Schulte T, Moliner-Morro A, et al. An Alpaca Nanobody Neutralizes SARS-CoV-2 by Blocking Receptor Interaction. Nat Commun (2020) 11(1). doi: 10.1038/s41467-020-18174-5

20. Wu Y, Li C, Xia S, Tian X, Kong Y, Wang Z, et al. Identification of Human Single-Domain Antibodies Against SARS-CoV-2. Cell Host Microbe (2020) 27(6):891–+. doi: 10.1016/j.chom.2020.04.023

21. Dong J, Huang B, Jia Z, Wang B, Kankanamalage SG, Titong A, et al. Development of Multi-Specific Humanized Llama Antibodies Blocking SARS-CoV-2/ACE2 Interaction With High Affinity and Avidity. Emerg Microbes Infect (2020) 9(1):1034–6. doi: 10.1080/22221751.2020.1768806

22. Nambulli S, Xiang YF, Tilston-Lunel NL, Rennick LJ, Sang Z, Klimstra WR, et al. Inhalable Nanobody (PiN-21) Prevents and Treats SARS-CoV-2 Infections in Syrian Hamsters at Ultra-Low Doses. Sci Adv (2021) 7(22):eabf0319. doi: 10.1126/sciadv.abf0319

23. Wang WL, Xu YL, Gao RQ, Lu RJ, Han K, Wu GZ, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA J Am Med Assoc (2020) 323(18):1843–4. doi: 10.1001/jama.2020.3786

24. Wu Y, Jiang S, Ying T. Single-Domain Antibodies As Therapeutics Against Human Viral Diseases. Front Immunol (2017) 8. doi: 10.3389/fimmu.2017.01802

25. Wu X, Cheng L, Fu M, Huang B, Zhu L, Xu S, et al. A Potent Bispecific Nanobody Protects Hace2 Mice Against SARS-CoV-2 Infection via Intranasal Administration. Cell Rep (2021) 37(3):109869. doi: 10.10111/2021.02.08.429275

26. Wu X, Li Y, Huang B, Ma X, Zhu L, Zheng N, et al. A Single-Domain Antibody Inhibits SFTSV and Mitigates Virus-Induced Pathogenesis In Vivo. JCI Insight (2020) 5(13):e136855. doi: 10.1172/jci.insight.136855

27. Wu X, Ma X, Li Y, Xu Y, Zheng N, Xu S, et al. Induction of Neutralizing Antibodies by Human Papillomavirus Vaccine Generated in Mammalian Cells. Antibody Ther (2019) 2(2):45–53. doi: 10.1016/j.antib.2019.04.004

28. Huang B, Zhu L, Wei H, Shi H, Zhang D, Yuan H, et al. Potent Neutralizing Humanized Antibody With Topical Therapeutic Potential Against HPV18-Related Cervical Cancer. Front Immunol (2021) 12(2339). doi: 10.3389/fimmu.2021.678318

29. Minor W, Cymborowski M, Otwinowski Z, Chruszcz M. HKL-3000: The Integration of Data Reduction and Structure Solution–From Diffraction Images to an Initial Model in Minutes. Acta Crystallogr D Biol Crystallogr (2006) 62(Pt 8):859–66. doi: 10.1107/S0907444906019949

30. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser Crystallographic Software. J Appl Crystallogr (2007) 40(Pt 4):658–74. doi: 10.1107/s0021889807021206

31. Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of M(pro) From SARS-CoV-2 and Discovery of its Inhibitors. Nature (2020) 582(7811):289–93. doi: 10.1038/s41586-020-2223-y

32. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and Development of Coot. Acta Crystallogr D Biol Crystallogr (2010) 66(4 Pt 4):486–501. doi: 10.1107/s0907444910007493

33. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, et al. PHENIX: A Comprehensive Python-Based System for Macromolecular Structure Solution. Acta Crystallogr D Biol Crystallogr (2010) 66(2 Pt 2):213–21. doi: 10.1107/s0907444909052925

34. Li J, Deng W, Huang Y, Gao H, Liu JN, Ren LL, et al. The Pathogenicity of SARS-CoV-2 in Hace2 Transgenic Mice. Nature (2020) 583(7818):8301. doi: 10.1038/s41586-020-2312-y

35. Cao YL, Su B, Guo XH, Sun WJ, Deng YQ, Bao LL, et al. Potent Neutralizing Antibodies Against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells. Cell (2020) 182(1):73–+. doi: 10.1016/j.cell.2020.05.025

36. Xu S, Ji X, Nawaz W, Liu B, Zhang F, Liu Y, et al. Infection of Humanized Mice With a Novel Phlebovirus Presented Pathogenic Features of Severe Fever With Thrombocytopenia Syndrome. PLoS Pathog (2021) 17(5):e1009587. doi: 10.1371/journal.ppat.1009587

37. Guttiler T, Akau M, Dickmanns A, Stemmgl KM, Gregor K, Rees R, et al. Neutralization of SARS-CoV-2 by Highly Potent, Hyperthermostable, and Mutation-Tolerant Nanobodies. EMBO J (2021) 40(19):e107985. doi: 10.15252/embj.2021107985

38. Wrapp D, De Vlieger D, Corbett KS, Torres GM, Wang N, Van Breedam W, et al. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. Cell (2020) 181(6):1436–41. doi: 10.1016/j.cell.2020.05.047

39. Steeland S, Vandenbroucke RE, Libert C. Nanobodies as Therapeutics: Big Opportunities for Small Antibodies. Drug Discovery Today (2016) 21(7):1076–111. doi: 10.1016/j.drudis.2016.04.003

40. Dai L, Gao GF. Viral Targets for Vaccines Against COVID-19. Nat Rev Immunol (2021) 21(2):73–82. doi: 10.1038/s41577-020-04080-0

41. Koenig PA, Das H, Liu HJ, Kummerer BM, Gehr FN, Jenster LM, et al. Structure-Guided Multivalent Nanobodies Block SARS-CoV-2 Infection and Suppress Mutational Escape. Science (2021) 371(6530):691+. doi: 10.1126/science.abe6230

42. Taylor PC, Adams AC, Hufford MM, de la Torre J, Winthrop K, Gottlieb RL. Neutralizing Monoclonal Antibodies for Treatment of COVID-19. Nat Rev Immunol (2021) 21(6):382–93. doi: 10.1038/s41577-021-00542-x

Conflict of Interest: Author LZ was employed by the company Abrev Biotechnology Co., Ltd. Author SX is employed by the Y-Clone Medical Science Co., Ltd. A patent application on 2A12 was submitted by the Y-Clone Medical Science Co., Ltd., under CN201911358261X.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Wu, Wang, Cheng, Ni, Zhu, Ma, Huang, Ji, Hu, Li, Xu, Shi, Zhang, Liu, Nawaz, Hu, Ye, Liu and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.